5 sources · checked 33 times, last 2d ago
The sources report 28.6 billion won as cumulative funding, not this round’s amount. Source 1 says six new institutional investors but names only five; no unnamed investor is added.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $13.7M 28.6B won financing total 18.3 billion won | ~ 2026-09 | Premier Partners | No recent discussion |
5 sources · checked 33 times, last 2d ago [ VERIFIED ] read against 4 of 5 sources The sources report 28.6 billion won as cumulative funding, not this round’s amount. Source 1 says six new institutional investors but names only five; no unnamed investor is added. | ||||
HITS says conventional drug discovery takes about 10 years and costs an average of 3 trillion KRW, while the odds of success are only 1 in 9,000, so its AI aims to reduce trial and error, cost, and experiment time. Its latest 18.3-billion-won Series B is funding an AI co-scientist that combines specialized models and research agents, with planned integration with automated laboratory equipment by 2027.
Checked against 10 sources on Sep 28
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Series A | 55억 원 | 2022-02-17 | Korea Investment Partners | |
Also named as backers in company research: Schmidt Inc., Capstone Partners Inc., Kiwoom Investment, Company K Partners, STIC Ventures, TIPS project (Ministry of SMEs and Startups)